**EOC317**

**Cat. No.:** HY-16025  
**CAS No.:** 93980-30-8  
**Molecular Formula:** C_{27}H_{26}F_{5}N_{7}O_{3}  
**Molecular Weight:** 591.53  
**Target:** FGFR; VEGFR  
**Pathway:** Protein Tyrosine Kinase/RTK  
**Storage:**  
- Powder  
  -20°C  3 years  
  4°C  2 years  
- In solvent  
  -80°C  6 months  
  -20°C  1 month

## SOLVENT & SOLUBILITY

### In Vitro

DMSO: \(\geq 35 \text{ mg/mL} \ (59.17 \text{ mM})\)

*“≥” means soluble, but saturation unknown.*

<table>
<thead>
<tr>
<th>Preparing Stock Solutions</th>
<th>Solvent Concentration</th>
<th>1 mg</th>
<th>5 mg</th>
<th>10 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1 mM</td>
<td>1.6905 mL</td>
<td>8.4527 mL</td>
<td>16.9053 mL</td>
</tr>
<tr>
<td></td>
<td>5 mM</td>
<td>0.3381 mL</td>
<td>1.6905 mL</td>
<td>3.3811 mL</td>
</tr>
<tr>
<td></td>
<td>10 mM</td>
<td>0.1691 mL</td>
<td>0.8453 mL</td>
<td>1.6905 mL</td>
</tr>
</tbody>
</table>

Please refer to the solubility information to select the appropriate solvent.

## BIOLOGICAL ACTIVITY

### Description
EOC317 (ACTB-1003) is an oral kinase inhibitor with \(IC_{50}\)s of 6, 2 and 4 nM for FGFR1, VEGFR2 and Tie-2.

### \(IC_{50}\) & Target

<table>
<thead>
<tr>
<th>Target</th>
<th>(IC_{50})</th>
</tr>
</thead>
<tbody>
<tr>
<td>FGFR1</td>
<td>6 nM</td>
</tr>
<tr>
<td>VEGFR2</td>
<td>2 nM</td>
</tr>
<tr>
<td>Tie-2</td>
<td>4 nM</td>
</tr>
</tbody>
</table>

### In Vitro

EOC317 (ACTB-1003) is an oral kinase inhibitor with multiple modes of action, targeting cancer mutations via FGFR inhibition FGFR1 (\(IC_{50}=6 \text{ nM}\)), angiogenesis through inhibition of VEGFR2 (2 nM), Tie-2 (4 nM), and induces apoptosis likely by targeting RSK (5 nM) and p70S6K (32 nM). EOC317 is highly active with dose-dependent tumor growth inhibition in cell lines with FGFR genetic alterations-OPM2 human multiple myeloma and the murine leukemia Ba/F3-TEL-FGFR1. OPM2 cells harbor the FGFR3 t(4:14) translocation, FGFR3 K650E mutation and PTEN deletion while the Ba/F3-TEL-FGFR1 cells are driven by FGFR1 over-expression\[1\].

### In Vivo

EOC317 (ACTB-1003) is shown to inhibit tumor angiogenesis evident by the inhibition of CD31 staining in tumor
sections. EOC317 is combinable with 5-FU or paclitaxel without diminishing the activity or increasing the toxicity of these chemotherapy agents in the HCT-116 colon tumor xenograft model[1].

**REFERENCES**


---

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898  Fax: 609-228-5909  E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)